

Peer Reviewed Publications from GSTT Haemophilia &Thrombosis clinical and laboratory team in 2014

1. The pathogenesis of traumatic coagulopathy.
Cap A, **Hunt BJ**.
Anaesthesia. 2015 Jan;70 Suppl 1:96-e34. doi: 10.1111/anae.12914.
- 2.The current place of tranexamic acid in the management of bleeding.
Hunt BJ.
Anaesthesia. 2015 Jan;70 Suppl 1:50-e18. doi: 10.1111/anae.12910.
- 3.Blood - the most important humour?*.
Bailey CR, Klein AA, **Hunt BJ**.
Anaesthesia. 2015 Jan;70 Suppl 1:1-e1.
4. Acute traumatic coagulopathy.
Cap A, **Hunt B**.
Curr Opin Crit Care. 2014 Dec;20(6):638-45.
5. Thrombosis: A major contributor to global disease burden.
ISTH Steering Committee for World Thrombosis Day; ISTH Steering Committee for World Thrombosis Day (**Hunt**).
Thromb Res. 2014 Nov;134(5):931-938.
6. Thrombosis: a major contributor to global disease burden.
Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, **Hunt BJ**, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI; ISTH Steering Committee for World Thrombosis Day.
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2363-71.
7. Thrombosis: a major contributor to global disease burden.
Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, **Hunt BJ**, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI; ; ISTH Steering Committee for World Thrombosis Day.
Semin Thromb Hemost. 2014 Oct;40(7):724-35. doi: 10.1055/s-0034-1390325. Epub 2014 Oct 10.
8. Thrombosis: a major contributor to the global disease burden.
ISTH Steering Committee for World Thrombosis Day (**Hunt**).
J Thromb Haemost. 2014 Oct;12(10):1580-90.
9. Thrombosis: A major contributor to global disease burden.
ISTH Steering Committee for World Thrombosis Day; ISTH Steering Committee for World Thrombosis Day.(**Hunt**)
Thromb Haemost. 2014 Nov 3;112(5):843-52.
10. New oral anticoagulants in the management of venous thromboembolism: a major advance?
Sciascia S, Hunt BJ.
Eur J Vasc Endovasc Surg. 2014 Nov;48(5):487-8.



11. Lack of association of serum mannose/mannan binding lectin or ficolins with complement activation in patients with antiphospholipid antibodies.

Breen KA, Kilpatrick DC, Swierzko AS, Cedzynski M, **Hunt BJ**.

Blood Coagul Fibrinolysis. 2014 Sep;25(6):644-5.

12. When should we use diagnostic imaging to investigate for pulmonary embolism in pregnant and postpartum women?

Goodacre S, Nelson-Piercy C, **Hunt B**, Chan WS.

Emerg Med J. 2014 Jul 9. pii: emermed-2014-203871.

13. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators (**Hunt**).

Circulation. 2014 Jul 8;130(2):138-46.

14. Bleeding and coagulopathies in critical care.

Hunt BJ.

N Engl J Med. 2014 May 29;370(22):2153.

15. Impact of the national venous thromboembolism risk assessment tool in secondary care in England: retrospective population-based database study.

Catterick D, **Hunt BJ**.

Blood Coagul Fibrinolysis. 2014 Sep;25(6):571-6.

16. The differential diagnosis of splachnic vein thrombosis.

Chatziantoniou V, **Hunt BJ**.

Br J Haematol. 2014 May;165(4):578-9. doi: 10.1111/bjh.12773.

17. Bleeding and coagulopathies in critical care.

Hunt BJ.

N Engl J Med. 2014 Feb 27;370(9):847-59.

18. Testing for thrombophilia: clinical update.

Graham N, Rashid H, **Hunt BJ**.

Br J Gen Pract. 2014 Feb;64(619):e120-2. doi: 10.3399/bjgp14X677310.

19. The utility of the Wells clinical prediction model and ventilation-perfusion scanning for pulmonary embolism diagnosis in pregnancy.

Cutts BA, Tran HA, Merriman E, Nandurkar D, Soo G, DasGupta D, Prassannan N, **Hunt BJ**.

Blood Coagul Fibrinolysis. 2014 Jun;25(4):375-8.

20. How we manage the haematological aspects of major obstetric haemorrhage.

Allard S, Green L, **Hunt BJ**.

Br J Haematol. 2014 Jan;164(2):177-88.

21. Excellence, quality and limitations of the NICE venous thromboembolism score tool: how can it be improved?

Cohen AT, Granziera S.



Br J Haematol. 2014 Dec;167(5):702-4.

22. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.

Mebazaa A, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Merli G, Schellong SW, Spyropoulos AC, Tapson VF, De Sanctis Y, **Cohen AT**. Circulation. 2014 Jul 29;130(5):410-8.

23. Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy.

Granziera S, **Cohen AT**.

Evid Based Med. 2014 Oct;19(5):180.

24. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.

Cohen AT, Imfeld S, Rider T.

Adv Ther. 2014 May;31(5):473-93.

25. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction).

Alikhan R, Bedenis R, **Cohen AT**.

Cochrane Database Syst Rev. 2014 May 7;5:CD003747.

26. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study.

Smith JD, Baillie J, Baglin T, Griffiths GO, Casbard A, Cohen D, Fitzmaurice DA, Hood K, Rose P, **Cohen AT**, Johnson M, Maraveyas A, Bell J, Toone H, Nelson A, Noble SI. Trials. 2014 Apr 12;15:122.

27. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer.

Martinez C, **Cohen AT**, Bamber L, Rietbrock S.

Thromb Haemost. 2014 Aug;112(2):255-63.

28. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

29. Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ.

Am Heart J. 2014 Mar;167(3):335-41.

30. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.

Cohen AT, Spiro TE, Spyropoulos AC, Desantis YH, Homering M, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Tapson VF, Burton P; MAGELLAN Study Group.

J Thromb Haemost. 2014 Apr;12(4):479-87.

31. Managing pulmonary embolism from presentation to extended treatment.

Cohen AT, Dobromirski M, Gurwith MM.

Thromb Res. 2014 Feb;133(2):139-48. doi: 10.1016/j.thromres.2013.09.040. Epub 2013 Oct 14. Review.



32. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.

Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, Clark A, Creagh D, Rayment R, **Mcdonald V**, Roy A, Evans G, McGuckin S, Ni Ainle F, Maclean R, Lester W, Nash M, Scott R, O'Brien P; collaborators of the UK TTP Registry. *Blood*. 2014 Jul 10;124(2):211-9.

33. Raso Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: Case series and review of the literature. *Autoimmun Rev*. 2015 Jan;14(1):36-42.

S, Sciascia S, Kuzenko A, Castagno I, Marozio L, Bertero MT. *j.autrev*.2014.09.002. Epub 2014 Sep 18..

34. Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. **Sciascia S**, Bertolaccini ML. *Lupus*. 2014 Oct;23(12):1309-12

35. Thrombotic risk assessment in APS: the Global APS Score (GAPSS). Sciascia S, Bertolaccini ML. *Lupus*. 2014 Oct;23(12):1286-7.

36. The global anti-phospholipid syndrome score in primary APS.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. *Rheumatology (Oxford)*. 2014 Aug 13. pii: keu307. [Epub ahead of print] PubMed PMID: 25122726.

37. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort.

Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. *Arthritis Care Res (Hoboken)*. 2014 Dec;66(12):1915-20.

38. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. **Sciascia S**, Bertolaccini ML, Roccatello D, Khamashta MA, Sanna G. *J Neurol*. 2014 Sep;261(9):1706-14.

39. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. **Sciascia S**, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, Bertolaccini ML; on behalf of APS Action. *Ann Rheum Dis*. 2014 Jun 18. pii: annrheumdis-2014-205663.

40. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni P, Ortel TL, Petri M, Rahman A, Roubey R, **Sciascia S**, Snyder M, Tebo AE, Tincani A, Willis R. *Autoimmun Rev*. 2014 Sep;13(9):917-30.

41. Targeted therapy in antiphospholipid syndrome. **Sciascia S**, Khamashta MA, D'Cruz DP. *Curr Opin Rheumatol*. 2014 May;26(3):269-75. .

42. Renal involvement in antiphospholipid syndrome. **Sciascia S**, Cuadrado MJ, Khamashta M, Roccatello D. *Nat Rev Nephrol*. 2014 May;10(5):279-89..



43. New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. **Sciascia S**, Khamashta MA, Bertolaccini ML. *Curr Rheumatol Rep*. 2014 May;16(5):415.
44. Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. **Sciascia S**, Sanna G, Murru V, Khamashta MA, Bertolaccini ML. *Thromb Res*. 2014 Mar;133(3):451-4.
45. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. **Sciascia S**, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. *Thromb Haemost*. 2014 Feb;111(2):354-64.
46. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Camara I, **Sciascia S**, Simoes J, Pazzola G, Salas V, Karim Y, Roccatello D, Cuadrado MJ. *Clin Exp Rheumatol*. 2014 Jan-Feb;32(1):41-7.
47. Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio. **Moore GW, de Jager N, Cutler JA**. *Thromb Res*. 2014 Nov 4. pii: S0049-3848(14)00580-5.
48. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. **Moore GW**. *Int J Lab Hematol*. 2014 Jun;36(3):364-73..
49. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. **Moore GW**. *Semin Thromb Hemost*. 2014 Mar;40(2):163-71.
50. Complete prekallikrein deficiency masquerading as a lupus anticoagulant. **Moore GW**, Sangle SR, **Archer RA, Maloney JC, Rahman A**, D'Cruz DP. *Thromb Res*. 2014 Feb;133(2):301-2.
51. High sensitivity and specificity of a new functional flow cytometry assay for clinically significant heparin-induced thrombocytopenia antibodies. Garritsen HS, Probst-Keppler M, Legath N, Eberl W, Samaniego S, Woudenberg J, Schuitemaker JH, Kroll H, **Gurney DA, Moore GW**, Zehnder JL. *Int J Lab Hematol*. 2014 Apr;36(2):135-43.
52. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, **Bevan D**, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. *N Engl J Med*. 2014 Nov 20;371(21):1994-2004.
53. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study. Alamelu J, **Bevan D**, Sorensen B, Rangarajan S. *J Thromb Haemost*. 2014 Oct 14.



54. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.

Rea CJ, Foley JH, **Bevan DH**, Sørensen B.
Ann Hematol. 2014 Apr;93(4):683-92.

55. A national survey of immunosuppression strategies for acquired haemophilia A.

Batty P¹, Palmer B, Chalmers E, Hay CR, Liesner R, **Rangarajan S**, Talks K, Williams M, Collins P, Hart DP.
Haemophilia. 2014 Nov 24.

56. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort

comparison. Hay CR¹, Palmer BP, Chalmers EA, Hart DP, Liesner R, **Rangarajan S**, Talks K, Williams M, Collins PW. Haemophilia. 2014 Nov 7.

57. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

Collins PW¹, Palmer BP², Chalmers EA³, Hart DP⁴, Liesner R⁵, **Rangarajan S**⁶, Talks K⁷, Williams M⁸, Hay CR⁹; UK Haemophilia Centre Doctors' Organization.
Blood. 2014 Nov 27;124(23):3389-97.

58. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.

Rangarajan S¹, Jiménez-Yuste V, Santagostino E.
Haemophilia. 2014 Nov;20(6):e414-7.

59. Rationale for individualizing haemophilia care.

Sørensen B¹, Auerswald G, Benson G, Elezoviæ I, Felder M, Lambert T, Morfini M, Remor E, Salaj P, Santagostino E, Salek SZ, Ljung R.
Blood Coagul Fibrinolysis. 2014 Nov 13. [Epub ahead of print]

60. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.

Oldenburg J¹, **Austin SK**, Kessler CM.
Haemophilia. 2014 Sep;20 Suppl 6:17-26.

61. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

Lentz SR¹, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adeptTM2 investigators. (**Austin**)
J Thromb Haemost. 2014 Aug;12(8):1244-53.

62. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.

Lalezari S, Coppola A, Lin J, Enriquez MM, Tseneklidou-Stoeter D, Powell J, Ingerslev J; LIPLONG Investigators (**Austin**).
Haemophilia. 2014 May;20(3):354-61.

63. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

Mahlangu J¹, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF; A-LONG Investigators (**Austin**).
Blood. 2014 Jan 16;123(3):317-25.



64. Laboratory testing for the lupus anticoagulant. Approved guideline – first edition. Ledford-Kraemer MR (Chair), **Moore GW (Vice-Chair)**, Bottenus R, Daniele C, de Groot PG, Exner T, Favaloro EJ, Moffat KA, Nichols WL. CLSI document H60-A. Clinical and Laboratory Standards Institute Wayne, PA, USA April 2014
65. Vitamin K and other markers of micro-nutrient status in morbidly obese patients before bariatric surgery. Ewang-Emukowhate M, **Harrington DJ, Botha A**, McGowan B, Wierzbicki AS. Int J Clin Pract. Accepted for publication 28th October 2014.
66. Superwarfarin poisoning and its management. **Card DJ**, Sebastian F, Deuchande K, **Harrington DJ**. BMJ Case Rep 2014. doi:10.1136/bcr-2014-206360 1
67. Vitamin K metabolism: current knowledge and future research. **Card DJ, Gorska R, Cutler J, Harrington DJ**. Mol Nutr Food Res. 2014; 58: 1590-00
68. Molecular basis and bleeding manifestations of factor XI deficiency in 11 Turkish families. Keskin EY, Gürsel T, Kaya Z, Dai L, Koçak U, Yenicesu I, Belen FB, **Mitchell M**. Blood Coagul Fibrinolysis. 2014 Aug 23. [Epub ahead of print]
69. A novel mutation in the P2Y₁₂ receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding. Patel YM, Lordkipanidzé M, Lowe GC, Nisar SP, Garner K, Stockley J, Daly ME, **Mitchell M**, Watson SP, Austin SK, Mundell SJ. J Thromb Haemost. 2014 May;12(5):716-25..
70. [The von Willebrand factor predicted unpaired cysteines are essential for secretion.](#) Shapiro SE, Nowak AA, Wooding C, Birdsey G, Laffan MA, McKinnon TA. J Thromb Haemost. 2014 Feb;12(2):246-54.
71. Ongoing risk of thrombosis with factor XI concentrate: five years experience in two centres
Batty, Paul; Honke, Anja; Bowles, Louise; Hart, Dan; Pasi, John; Uprichard, James; **Austin, Steve**
Haemophilia, in press.
72. When should we use diagnostic imaging to investigate for pulmonary embolism in pregnant and postpartum women? Goodacre S, Nelson-Piercy CN, **Hunt B**, Chan W-S. Emerg Med 2015; 32: 78-82
73. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. **Sciasco S, Breen K, Hunt BJ**. Blood Coag & Fibrin 2015 in press
74. [Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay.](#) Lordkipanidzé M, Lowe GC, Kirkby NS, Chan MV, Lundberg MH, Morgan NV, Bem D, Nisar SP, Leo VC, Jones ML, Mundell SJ, Daly ME, Mumford AD, Warner TD, Watson SP; UK Genotyping and Phenotyping of **Platelets** Study Group (**Austin**). Blood. 2014 Feb 20;123(8):e11-22.



75. Endothelial and platelet microparticles in patients with antiphospholipid antibodies.
Breen KA, Sanchez K, Kirkman N, Seed PT, Parmar K, Moore GW, Hunt BJ.
Thromb Res. 2014 Dec 4.

76. Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis.
Shearer MJ, Newman P.
J Lipid Res 2014 Mar; 55(3):345–62.

77. Vitamin K metabolism in the fetus and neonate
Shearer MJ
Chapter for 5th Edition of Fetal and Neonatal Physiology, Elsevier (In Press)